The PrEP Access and Coverage Act of 2026 directs federal programs and private plans to cover FDA‑approved drugs and the full package of services used to prevent HIV—drugs, associated labs and diagnostics, administrative fees, and follow-up care—and it removes several common administrative barriers such as preauthorization for those services. It extends these coverage requirements across private insurance (including grandfathered plans), the Federal Employees Health Benefits Program, Medicare Parts B and D, Medicaid and CHIP, the Department of Veterans Affairs, the Department of Defense (TRICARE), and the Indian Health Service.
The bill also creates federal grants and public‑education/provider education campaigns to expand PrEP and PEP access; prohibits life, disability, and long‑term‑care insurers from denying or charging more because someone uses HIV‑prevention medication; requires HHS and other agencies to issue guidance and collect compliance data; and provides a private right of action with fee‑shifting for individuals harmed by noncompliance. For compliance officers, payers, state Medicaid programs, and providers this is primarily an operational and billing overhaul: new mandatory benefits, eliminated cost‑sharing in many programs, reporting obligations, and a narrower role for utilization management tools.
At a Glance
What It Does
The bill amends the Public Health Service Act, ERISA, the Internal Revenue Code, and multiple federal program statutes to classify FDA‑approved HIV prevention drugs and their associated services as covered preventive care and, in core programs, removes cost‑sharing. It explicitly prohibits preauthorization for those services except in a narrow therapeutic‑equivalence circumstance, creates a grant program for PrEP/PEP delivery and outreach, and directs agencies to issue guidance and collect insurer compliance data.
Who It Affects
Group health plans and individual issuers, ERISA plan sponsors, Medicare Parts B and D plan sponsors, state Medicaid and CHIP programs, FEHB carriers, VA and TRICARE programs, Indian Health Service providers, community clinics and nonprofit providers that receive grants, and life/disability/long‑term‑care insurers subject to the non‑discrimination rule.
Why It Matters
This bill establishes a federal floor that removes two major access barriers—out‑of‑pocket costs and many preauthorization requirements—potentially increasing PrEP/PEP uptake and changing utilization patterns for antiretrovirals. It also forces payers and federal health programs to adapt billing, coding, and confidentiality practices and creates a new enforcement and reporting architecture that stakeholders must operationalize.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
At its core, the Act treats FDA‑approved drugs used for HIV prevention—together with the lab tests, diagnostics, administrative fees, and clinical follow‑up that accompany their use—as essential preventive services. For private coverage it inserts those products and services into the preventive benefits list in the Public Health Service Act and then adds parallel prohibitions on preauthorization across PHSA, ERISA, and the Internal Revenue Code.
The preauthorization ban is not absolute: a plan may require preauthorization for a particular drug only if the plan accepts a therapeutically equivalent drug without preauthorization.
For federal programs the bill takes multiple routes. It requires FEHB plans to cover prevention drugs and associated services without cost‑sharing.
It adds an explicit Medicaid benefit category called “HIV prevention services,” mandates no cost‑sharing for those services for Medicaid enrollees, and instructs states to include the services in benchmark coverage; similar language makes CHIP coverage mandatory for targeted children and pregnant women. For Medicare, the Act classifies HIV prevention services under Part B and directs payment at 100 percent (eliminating Part B coinsurance and exempting the services from the Part B deductible), and it separately amends Part D to remove the Part D deductible and any cost‑sharing for covered drugs used for HIV prevention.The bill also extends no‑cost coverage to VA beneficiaries and TRICARE enrollees, directs the Indian Health Service to provide funding without limitation for approved HIV prevention drugs and related services, and requires HHS to modify HIPAA‑linked regulations to protect confidentiality for family plan members accessing these benefits.
To expand uptake, it funds a CDC‑led public education campaign and a provider education effort and establishes a competitive grant program that can fund drugs, labs, outreach, provider training, adherence programs, and PrEP navigators at FQHCs, rural clinics, community organizations, and other eligible entities.On compliance and enforcement, the Act requires HHS (coordinating with Labor and Treasury) to issue implementation guidance, develop billing/coding materials, provide technical assistance to state regulators and eligible entities, and to collect annual reporting from plans for ten years—aggregate claims counts and cost‑sharing data—to monitor compliance. It creates a private right of action that permits individuals to sue noncompliant plans or issuers and mandates fee‑shifting for prevailing plaintiffs.
Finally, the Act contains a clause stating it applies notwithstanding other law, which signals Congress intends these coverage requirements to be binding even where they intersect with earlier statutes.
The Five Things You Need to Know
Most coverage and cost‑sharing changes take effect for plan years beginning on or after January 1, 2027, with a limited delay for states that require legislation to comply.
The preauthorization prohibition permits an exception only when a plan requires prior authorization for a particular FDA‑approved drug but simultaneously covers a therapeutically equivalent product without any prior authorization.
HHS will require each group health plan and issuer to submit aggregate compliance data at least annually for ten years, including the number of HIV prevention claims and any enrollee cost‑sharing for those claims.
The bill creates a federal grant program for states, territories, tribes, and directly eligible entities (including FQHCs, family planning grantees, rural health clinics, and nonprofit organizations) to cover PrEP/PEP drugs, diagnostics, outreach, adherence services, and PrEP navigators.
It establishes a private right of action for any person aggrieved by violations of the Act and requires courts to award costs and reasonable attorney fees to prevailing plaintiffs.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Private‑plan preventive benefit plus preauthorization limits
This subsection amends PHSA section 2713 by inserting an explicit preventive service category for any FDA‑approved drug used to prevent HIV and the full suite of associated services. It then creates parallel statutory prohibitions on preauthorization across the PHSA, ERISA, and the tax code, while carving out a narrow exception that allows plans to require prior authorization for a particular drug only when a therapeutically equivalent drug is available without preauthorization. Practically, this forces insurers to reclassify certain antiretrovirals as preventive care, adjust formularies, and change utilization‑management protocols and pharmacy benefit operations.
Medicaid and CHIP mandatory benefits and no cost‑sharing
The bill adds a new Medicaid benefit line—'HIV prevention services'—covering prevention drugs, labs, diagnostics, and follow‑up. It bars states from imposing cost‑sharing for those services in Medicaid and requires inclusion of those services in benchmark EHB‑equivalent coverage where applicable. For CHIP, it mandates the same coverage for targeted low‑income children and pregnancy‑related assistance. The statute includes an effective date (January 1, 2027) and a safety valve allowing delayed state implementation if state legislation is necessary.
Medicare Parts B and D: coverage classification and elimination of cost‑sharing
For Part B the bill adds 'HIV prevention services' to the statute's list of covered outpatient items, defines the term in statute, directs Medicare to pay 100 percent for those services (removing coinsurance and the Part B deductible for them), and applies this to items furnished on or after January 1, 2027. For Part D it amends the statutory structure to eliminate the Part D deductible, coinsurance, and cost‑sharing for covered drugs used to prevent HIV, and it adjusts low‑income subsidies and related rules to reflect that no‑cost drugs should be treated differently in cost‑sharing calculations.
Federal employee, VA, DoD, and IHS coverage expansions
FEHB plans must include coverage for prevention drugs and related services without cost‑sharing. The VA cost‑sharing regime is adjusted to exempt prevention medications and their diagnostic and monitoring services from copayments; VA explicitly lists such drugs as preventive benefits. The DoD/TRICARE side receives a statutory requirement to cover the full package without cost‑sharing for TRICARE beneficiaries. The Indian Health Service receives a statutory provision authorizing unlimited funding for approved prevention drugs and associated services (subject to annual appropriations). These changes require program administrators to update formularies, copayment rules, and pharmacy operations.
Public and provider education campaigns; PrEP/PEP grant fund
The CDC will run a culturally competent public education campaign tailored to high‑need communities to increase awareness, address stigma, and promote access to PrEP and PEP; an accompanying provider education campaign targets clinician readiness and cultural competency. Separately, HHS must establish a competitive grant program to distribute funds to states, tribes, territories, and directly eligible entities (including FQHCs, rural clinics, family planning grantees, and community nonprofits). Grants may pay for drugs, labs, outreach, adherence supports, and personnel such as PrEP navigators, and grantees must submit plans describing how funds will reduce disparities.
Insurance nondiscrimination, private suits, and enforcement architecture
Section 4 bars life, disability, and long‑term‑care insurers from denying coverage or raising premiums solely because an individual takes medication to prevent HIV. The bill creates a private right of action (fee‑shifting for prevailing plaintiffs) and directs HHS, Labor, and Treasury to monitor compliance, issue guidance, provide technical assistance, and collect annual insurer reports for ten years. The enforcement provisions combine administrative monitoring with private litigation as parallel enforcement routes.
Confidentiality for family plans
HHS must amend HIPAA‑adjacent regulations to ensure a family plan member can access HIV prevention benefits without alerting other plan members—including the primary policyholder—through explanations of benefits or routine notices. This requires administrative changes to EOB practices and may implicate state insurance filing forms and carrier systems.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Individuals at risk of HIV, especially uninsured or underinsured people: they gain access to drugs, diagnostic testing, and follow‑up without cost‑sharing in multiple federal programs and, in many cases, under private coverage.
- Medicare beneficiaries who seek PrEP: Part B reclassification and Part D cost‑sharing elimination removes deductible and coinsurance barriers for outpatient prevention services and drugs.
- Veterans and active‑duty families: VA beneficiaries and TRICARE enrollees receive statutory no‑cost coverage and exemption from medication copayments for prevention drugs and related services.
- Community health centers, rural clinics, family planning grantees, and nonprofits: eligible entities can receive grant funding for drugs, outreach, adherence programs, and PrEP navigators, strengthening local delivery capacity.
- Groups historically underserved in PrEP uptake (communities of color, LGBTQ+ communities): the bill mandates culturally competent public and provider education and requires evaluation metrics focused on reducing disparities.
Who Bears the Cost
- Private insurers and group health plans (including ERISA plans and FEHB carriers): they must cover additional drugs and services as preventive benefits and adjust utilization management, which could increase short‑term pharmacy and clinical costs.
- Medicare Trust Funds and federal budgets: shifting Part B payment rules to 100 percent for prevention services and eliminating Part D cost‑sharing may increase federal outlays; grant and education programs also require appropriations.
- State Medicaid programs and budgets: although federal match applies, states must integrate the new mandatory benefit and absorb administrative implementation costs; states facing legislative requirements may incur transitional expenses.
- Life, disability, and long‑term‑care insurers: the nondiscrimination rule prohibits risk rating based solely on PrEP use, which insurers say may limit actuarial adjustments and raise concerns about adverse selection or pricing flexibility.
- Providers and health systems: they must update billing, coding, and confidentiality processes, invest in staff (e.g., PrEP navigators) and compliance activities, and coordinate with payers on reimbursement and prior‑authorization exceptions.
Key Issues
The Core Tension
The central dilemma is access versus control: the Act expands access by removing cost and administrative barriers to PrEP/PEP, which is likely to increase uptake and public‑health benefit, but it simultaneously strips payers of common utilization‑management tools and imposes new federal spending and administrative obligations—forcing choices between broader prevention gains and tighter budgetary or actuarial management.
The bill removes two common barriers—out‑of‑pocket costs and many preauthorization rules—but in doing so constrains payer tools used to control utilization and expenditures. The preauthorization ban includes only a narrow exception tied to therapeutic equivalence, which preserves a limited formulary management lever but leaves plans with fewer routine controls over initiation and renewal.
This raises questions about how payers will manage adherence monitoring and stewardship for antiretrovirals without traditional utilization management.
Fiscal and operational impacts are difficult to predict. Eliminating Part B coinsurance and Part D cost‑sharing for prevention drugs likely increases federal spending while shifting less cost to beneficiaries; however, higher uptake could produce population‑level HIV prevention savings that materialize over years rather than in annual program budgets.
States and carriers will need to modify eligibility systems, claims coding, EOB workflows, and confidentiality protections—tasks that require funding, time, and coordination. The Act directs HHS to issue guidance and collect compliance data, but the statute does not appropriate specific sums for implementation support, creating a potential mismatch between mandated changes and available administrative resources.
The nondiscrimination provision for life, disability, and long‑term‑care insurance addresses a genuine barrier to uptake but creates actuarial uncertainty for those product markets and may invite legal challenges about state regulation and scope. Finally, the confidentiality mandate (changing HIPAA‑adjacent regulations to protect family plan members) will require technical fixes to how carriers generate notices—a nontrivial operational challenge—while balancing insurers’ need for information to detect fraud and administer benefits.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.